Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
2C-E
2C-E, also known as 4-ethyl-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families. It is taken orally.
2C-E was first synthesized by Alexander Shulgin in 1977 and was documented in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-E's dose range as 10 to 25 mg orally and its duration as 8 to 12 hours. He describes 2C-E as having a steep dose–response curve, such that a small increase in dose can result in an unexpectedly large increase in effects. While a dose of 10 mg is often experienced as rich and well-tolerated, doses of 25 to 30 mg have been described as too much and as very frightening. The onset of 2C-E was not described.
2C-E's effects are often described as "neutral", in comparison with other psychedelics and even other 2C drugs.[citation needed] In PiHKAL, Shulgin states:
The effects of 2C-E have been formally clinically studied. Its effects included altered perceptions, hallucinations, and euphoria, among others. The onset was within 2 hours and its duration was more than 6 hours, although these parameters were not precisely measured.
Adverse effects of 2C-E include tachycardia, hypertension, agitation, delirium, and hallucinations. At least two deaths have been attributed to a 2C-E overdose.
2C-E is metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C-E. This may result in overdose and serious toxicity.
2C-E acts as a serotonin 5-HT2 receptor agonist. Activation of the serotonin 5-HT2A receptor is thought to be responsible for its psychedelic effects.[citation needed]
Hub AI
2C-E AI simulator
(@2C-E_simulator)
2C-E
2C-E, also known as 4-ethyl-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families. It is taken orally.
2C-E was first synthesized by Alexander Shulgin in 1977 and was documented in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-E's dose range as 10 to 25 mg orally and its duration as 8 to 12 hours. He describes 2C-E as having a steep dose–response curve, such that a small increase in dose can result in an unexpectedly large increase in effects. While a dose of 10 mg is often experienced as rich and well-tolerated, doses of 25 to 30 mg have been described as too much and as very frightening. The onset of 2C-E was not described.
2C-E's effects are often described as "neutral", in comparison with other psychedelics and even other 2C drugs.[citation needed] In PiHKAL, Shulgin states:
The effects of 2C-E have been formally clinically studied. Its effects included altered perceptions, hallucinations, and euphoria, among others. The onset was within 2 hours and its duration was more than 6 hours, although these parameters were not precisely measured.
Adverse effects of 2C-E include tachycardia, hypertension, agitation, delirium, and hallucinations. At least two deaths have been attributed to a 2C-E overdose.
2C-E is metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C-E. This may result in overdose and serious toxicity.
2C-E acts as a serotonin 5-HT2 receptor agonist. Activation of the serotonin 5-HT2A receptor is thought to be responsible for its psychedelic effects.[citation needed]